We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with Schizophrenia.
- Authors
Henderson, D. C.; Fan, X.; Sharma, B.; Copeland, P. M.; Borba, C. P.; Boxill, R.; Freudenreich, O.; Cather, C.; Eden Evins, A.; Goff, D. C.
- Abstract
Objective: The primary purpose of this 8-week double-blind, placebo-controlled trial of rosiglitazone 4 mg/day was to examine its effect on insulin sensitivity index (SI) and glucose utilization (SG) in clozapine-treated subjects with schizophrenia with insulin resistance. Method: Eighteen subjects were randomized and accessed with a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT) at baseline and at week 8 to estimate SG and SI. Results: Controlling for the baseline, comparing the rosiglitazone group with placebo group, there was a non-significant improvement in SG (0.016 ± 0.006–0.018 ± 0.008, effect size = 0.23, P = 0.05) with a trend of improvement in SI in the rosiglitazone group (4.6 ± 2.8–7.8 ± 6.7, effect size = 0.18, P = 0.08). There was a significant reduction in small low-density lipoprotein cholesterol (LDL-C) particle number (987 ± 443–694 ± 415, effect size = 0.30, P = 0.04). Conclusion: Rosiglitazone may have a role in addressing insulin resistance and lipid abnormalities associated with clozapine.
- Subjects
CLOZAPINE; SCHIZOPHRENIA treatment; PLACEBOS; INSULIN resistance; LIPOPROTEINS
- Publication
Acta Psychiatrica Scandinavica, 2009, Vol 119, Issue 6, p457
- ISSN
0001-690X
- Publication type
Article
- DOI
10.1111/j.1600-0447.2008.01325.x